Literature DB >> 18780564

The role of nitric oxide on the proliferation of a human osteoblast cell line stimulated with hydroxyapatite.

Wihaskoro Sosroseno1, Erwan Sugiatno, Abdul Rani Samsudin, Fikri Ibrahim.   

Abstract

The aim of the present study was to test the hypothesis that the proliferation of a human osteoblast cell line (HOS cells) stimulated with hydroxyapatite (HA) may be regulated by nitric oxide (NO). The cells were cultured on the surface of HA. Medium or cells alone were used as controls. L-arginine, D-arginine, 7-NI (an nNOS inhibitor), L-NIL (an iNOS inhibitor), L-NIO (an eNOS inhibitor) or carboxy PTIO, a NO scavenger, was added in the HA-exposed cell cultures. The cells were also precoated with anti-human integrin alphaV antibody. The levels of nitrite were determined spectrophotometrically. Cell proliferation was assessed by colorimetric assay. The results showed increased nitrite production and cell proliferation by HA-stimulated HOS cells up to day 3 of cultures. Anti-integrin alphaV antibody, L-NIO, or carboxy PTIO suppressed, but L-arginine enhanced, nitrite production and cell proliferation of HA-stimulated HOS cells. The results of the present study suggest, therefore, that interaction between HA and HOS cell surface integrin alphaV molecule may activate eNOS to catalyze NO production which, in turn, may regulate the cell proliferation in an autocrine fashion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18780564     DOI: 10.1563/0.910.1

Source DB:  PubMed          Journal:  J Oral Implantol        ISSN: 0160-6972            Impact factor:   1.779


  2 in total

1.  Is endothelial-nitric-oxide-synthase-derived nitric oxide involved in cardiac hypoxia/reoxygenation-related damage?

Authors:  A Rus; M A Peinado; S Blanco; M L Del Moral
Journal:  J Biosci       Date:  2011-03       Impact factor: 1.826

2.  Reversal of age-associated oxidative stress in mice by PFT, a novel kefir product.

Authors:  Mamdooh Ghoneum; Shaymaa Abdulmalek; Deyu Pan
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.